Session Details

Session Details

01:30 PM - 03:15 PM - Room 307-308

Donald Kohn - MD - Unversity of California, Los Angeles

Co-Chair

01:30 PM - 03:15 PM - Room 307-308

Tiffany Chen -

Co-Chair

01:30 PM - 01:45 PM - Room 307-308

Payam Zarin - PhD - GentiBio

39: An Allogeneic Engineered Tissue Treg Approach for the Treatment of Acute Ischemic and Inflammatory Diseases

01:45 PM - 02:00 PM - Room 307-308

Travis Drow - Seattle Children's Research Institute

40: Myelin-Specific Engineered Treg Exhibit Therapeutic Benefit in a Murine Model of Multiple Sclerosis

02:00 PM - 02:15 PM - Room 307-308

Mara Davis - University of Pennsylvania

41: Development of Chimeric Antigen Receptor Macrophages Targeting Amyloid-β in Alzheimer’s Disease

02:15 PM - 02:30 PM - Room 307-308

Joseph Skeate - PhD - University of Minnesota - Moriarity Lab

42: Base Editor Mediated CAR Integration with Simultaneous Multiplex Knockout for Enhanced Cancer Immunotherapies

02:30 PM - 02:45 PM - Room 307-308

Ellen Xu - Massachusetts Institute of Technology

43: Peptide-MHC-Targeted Retroviruses Expand and Deliver Therapeutic Cargoes to Rare Populations of Anti-Tumor T Cells

02:45 PM - 03:00 PM - Room 307-308

Adi Barzel - PhD - Tel Aviv University

44: T Cell Engineering Using V(D)J Recombination

03:00 PM - 03:15 PM - Room 307-308

Alex Garcia - PhD - Fate Therapeutics Inc.

45: Novel α3-MICA/B-Specific CAR T-Cell Immunotherapy Demonstrates Ubiquitous Targeting of Cancer Cells and Resistance to Immune-Surveillance Evasion